Latest News about MRK
Recent news which mentions MRK
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
From Benzinga
Here’s where to hunt for yield, according to a Fidelity fund manager
October 01, 2021
From MarketWatch
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
From Benzinga
Merck, Sutro Biopharma Extends Cytokine Derivative Research Program
September 30, 2021
From Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
From Benzinga
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
September 30, 2021
From Benzinga
A Peek Into The Markets: US Stock Futures Climb Ahead Of GDP, Jobless Claims Data
September 30, 2021
From Benzinga
Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show
September 29, 2021
From Benzinga
7 Biotech Stocks Entering the Golden Boom Phase
September 28, 2021
From InvestorPlace
Only 47 stocks in the S&P 500 have fallen over the past year — Wall Street predicts they will climb up to 54% in 12 months
September 28, 2021
From MarketWatch
Why Are I-Mab Shares Trading Higher On Tuesday?
September 28, 2021
From Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
From Benzinga
These sectors are looking so cheap that ESG considerations will have to be put on standby, strategist says
September 28, 2021
From MarketWatch
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
September 28, 2021
From Benzinga
A Peek Into The Markets: US Stock Futures Down Ahead Of Economic Data, Fed Speakers
September 28, 2021
From Benzinga
Moderna CEO Predicts Pandemic Could End in 2022: Here's Why the Stock Could Plunge If He's Right
September 28, 2021
From Motley Fool
5 Stocks To Watch For September 28, 2021
September 28, 2021
From Benzinga
Merck nears deal for rare-disease-drug maker Acceleron
September 28, 2021
From MarketWatch
Pfizer Begins Late-Stage Study To Test Effectiveness Of Oral Drug Against COVID-19 In Those Exposed To The Virus
September 28, 2021
From Benzinga
Merck's Keytruda Tops Placebo On Overall Survival Endpoint In Liver Cancer Patients
September 27, 2021
Tickers
MRK
From Benzinga
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
From Benzinga
Why AstraZeneca Stock Is Trading Higher Today
September 24, 2021
From Benzinga
AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients
September 24, 2021
From Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
September 21, 2021
From Benzinga
These 3 Dow Stocks Are Set to Soar in 2021's Second Half and Beyond
September 21, 2021
From Motley Fool
Apple And Disney Lead The Dow Jones Lower
September 20, 2021
From Benzinga
Here are the worst-performing U.S. stocks as the Evergrande crisis rattles investors
September 20, 2021
From MarketWatch
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
September 20, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.